Exposotypes in Psychotic Disorders

Competing Interest Statement

Dr. Clementz reports being on the KyNexis SAB and the B-SNIP Diagnostics, LLC Board of Managers. Dr. McDowell reports serving on the B-SNIP Diagnostics, LLC Board of Managers Dr. Keedy reports serving on the B-SNIP Diagnostics, LLC Board of Managers Dr. Ivleva reports serving on the B-SNIP Diagnostics, LLC Board of Managers. She also served on scientific advisory boards for Janssen Scientific Affairs, LLC, Alkermes, Inc, and Karuna Therapeutics. Dr. Gershon reports serving on the B-SNIP Diagnostics, LLC Board of Managers Dr. Keshavan reports serving on the B-SNIP Diagnostics, LLC Board of Managers Dr. Pearlson reports serving on the B-SNIP Diagnostics, LLC Board of Managers Dr. Tamminga reports serving on the Merck DSmB, being on the Karuna SAB and owning Karuna stock, and being on the KyNexis SAB and owning KyNexis stock, and B-SNIP Diagnostics, LLC Board of Managers. Other authors have no competing interests to declare.

Funding Statement

This study was funded by the National Institute of Mental Health (R21MH133001 to Dr. Yassin). Additional support was provided in part by NIMH grants MH-077851 (to CAT), MH-077945 (to GDP), MH-078113 (to MSK), MH-077862 (to JAS), MH-072767 (to SKH), and MH-103366 (to BAC), MH-103368 (to ESG).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The B-SNIP study protocol was approved by the institutional review board at each local site. After a complete description of the study to the volunteers, written informed consent was obtained. The sites IRB include: Department of Psychiatry, University of Texas Southwestern Medical School, Dallas; the Department of Psychiatry, Beth Israel Deaconess Hospital, Harvard Medical School, Boston; the Institute of Living, Hartford, Conn.; the Department of Psychiatry, Yale School of Medicine, New Haven, Conn.; the Department of Psychology, University of Georgia, Athens; the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore; and the University of Illinois School of Pharmacy, Chicago.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes